Intellia Therapeutics, Inc.

NasdaqGM NTLA

Intellia Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024

Intellia Therapeutics, Inc. Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Intellia Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -39.83%, a 16.52% change year over year.
Intellia Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -47.72%, a -39.43% change year over year.
Intellia Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -34.22%, a 14.75% change year over year.
Intellia Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -40.14%, a -21.64% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGM: NTLA

Intellia Therapeutics, Inc.

CEO	Dr. John M. Leonard M.D.
IPO Date	May 6, 2016
Location	United States
Headquarters	40 Erie Street
Employees	526
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years